TY - JOUR
T1 - Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease
AU - Muenchhoff, Julia
AU - Poljak, Anne
AU - Thalamuthu, Anbupalam
AU - Gupta, Veer B.
AU - Chatterjee, Pratishtha
AU - Raftery, Mark
AU - Masters, Colin L.
AU - Morris, John C.
AU - Bateman, Randall J.
AU - Fagan, Anne M.
AU - Martins, Ralph N.
AU - Sachdev, Perminder S.
N1 - Funding Information:
This work was facilitated by the National Institute of Ageing grant UF1 AG032438, JC Morris, PI; Australian National Health and Medical Research Council Program Grant 350833, Capacity Building Grant 568940, the Australian Research Council Discovery Project Grant DP120102078 and the Rebecca L. Cooper Medical Research Foundation.
PY - 2016/7/6
Y1 - 2016/7/6
N2 - The autosomal dominant form of Alzheimer's disease (ADAD) is far less prevalent than late onset Alzheimer's disease (LOAD), but enables well-informed prospective studies, since symptom onset is near certain and age of onset is predictable. Our aim was to discover plasma proteins associated with early AD pathology by investigating plasma protein changes at the asymptomatic and symptomatic stages of ADAD. Eighty-one proteins were compared across asymptomatic mutation carriers (aMC, n = 15), symptomatic mutation carriers (sMC, n = 8) and related noncarriers (NC, n = 12). Proteins were also tested for associations with cognitive measures, brain amyloid deposition and glucose metabolism. Fewer changes were observed at the asymptomatic than symptomatic stage with seven and 16 proteins altered significantly in aMC and sMC, respectively. This included complement components C3, C5, C6, apolipoproteins A-I, A-IV, C-I and M, histidine-rich glycoprotein, heparin cofactor II and attractin, which are involved in inflammation, lipid metabolism and vascular health. Proteins involved in lipid metabolism differed only at the symptomatic stage, whereas changes in inflammation and vascular health were evident at asymptomatic and symptomatic stages. Due to increasing evidence supporting the usefulness of ADAD as a model for LOAD, these proteins warrant further investigation into their potential association with early stages of LOAD.
AB - The autosomal dominant form of Alzheimer's disease (ADAD) is far less prevalent than late onset Alzheimer's disease (LOAD), but enables well-informed prospective studies, since symptom onset is near certain and age of onset is predictable. Our aim was to discover plasma proteins associated with early AD pathology by investigating plasma protein changes at the asymptomatic and symptomatic stages of ADAD. Eighty-one proteins were compared across asymptomatic mutation carriers (aMC, n = 15), symptomatic mutation carriers (sMC, n = 8) and related noncarriers (NC, n = 12). Proteins were also tested for associations with cognitive measures, brain amyloid deposition and glucose metabolism. Fewer changes were observed at the asymptomatic than symptomatic stage with seven and 16 proteins altered significantly in aMC and sMC, respectively. This included complement components C3, C5, C6, apolipoproteins A-I, A-IV, C-I and M, histidine-rich glycoprotein, heparin cofactor II and attractin, which are involved in inflammation, lipid metabolism and vascular health. Proteins involved in lipid metabolism differed only at the symptomatic stage, whereas changes in inflammation and vascular health were evident at asymptomatic and symptomatic stages. Due to increasing evidence supporting the usefulness of ADAD as a model for LOAD, these proteins warrant further investigation into their potential association with early stages of LOAD.
UR - http://www.scopus.com/inward/record.url?scp=84977596194&partnerID=8YFLogxK
U2 - 10.1038/srep29078
DO - 10.1038/srep29078
M3 - Article
C2 - 27381087
AN - SCOPUS:84977596194
SN - 2045-2322
VL - 6
JO - Scientific reports
JF - Scientific reports
M1 - 29078
ER -